Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
John Simard is Director at Xbiotech. OQRO lists 2 transactions filed with the SEC under this name, the latest on Nov 13, 2026, each linked to the official Form 4.
Director
Disclosures on record
2
Companies involved
1
2 purchases disclosed. $1,000 placed after each of the 1 purchases disclosed since 2025-11-14 would be worth $1K today ($1K put in); the same in the S&P 500 (SPY): $981.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
XbiotechXBIT
2 disclosures · Oct 2026 – Nov 2026 · 2 bought
Nov 3, 2026Bought~$143Kdisclosed Nov 13
DetailsOfficial recordOct 26, 2026Bought~$711Kdisclosed Oct 28
DetailsAs of the latest filing on , John Simard reported holding 4,261,690 shares of Xbiotech (XBIT), worth about $8.35M at the last close of $2 (Nov 13, 2026). In the last 12 months, John Simard bought $855K in 2 open-market purchases.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Xbiotech XBIT | 4,261,690 | 4.26M direct | $2 | $8.35M | Nov 3, 2026 |
Is this John Simard’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Nov 3, 2026, John Simard reported holding 4,261,690 shares of Xbiotech (XBIT). At the last close of $2 on Nov 13, 2026, that is about $8.35M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, John Simard reported 2 open-market purchases worth $855K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
John Simard bought shares on the open market in 2026. Sales in 1 of the 6 years since 2021.
In SEC filings since 2021: the latest open-market purchase is from 2026; the latest open-market sale is from 2021.
Xbiotech (XBIT), from 2021 to 2026: 2 purchases and 20 sales.
John Simard bought shares on the open market in 2026. Sales in 1 of the 6 years since 2021.
John Simard reported 2 open-market purchases and 20 sales since 2021; purchases in 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $855K2×2 trades | — |
| 2021 | — | $5.64M20×20 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
John Simard reported 2 open-market purchases and 20 sales here, 2021 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
